<DOC>
	<DOCNO>NCT01334086</DOCNO>
	<brief_summary>Chemotherapy induce nausea vomiting ( CINV ) major adverse effect chemotherapy . This study determine incidence vomiting/retching standard induction chemotherapy regimen patient acute myeloid leukemia ( AML ) also receive antiemetic know aprepitant . The standard frontline chemotherapy patient AML consist cytarabine give 7 day continuous infusion plus 3 day anthracycline , commonly daunorubicin , day 1-3 . This known 3+7 regimen . Antiemetic treatment usually give patient nausea vomit . Granisetron ( 5-HT3 receptor antagonist ) use 3 daunorubicin day antiemetic use breakthrough nausea/vomiting . This study test prophylactic use aprepitant , addition standard antiemetic regimen use Princess Margaret Hospital ( PMH ) , reduce incidence delay onset vomiting/retching Day 5 AML patient receive standard 3+7 regimen , compare retrospective data use regimen .</brief_summary>
	<brief_title>Aprepitant Antiemetic Prophylaxis Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Acute myeloid leukemia ( AML ) , subtype include acute promyelocytic leukemia ( APL ) . Patients either de novo secondary AML eligible . No prior AML induction chemotherapy . Due receive standard 3+7 induction chemotherapy use daunorubicin Days 13 , plus cytarabine continuous infusion daily Days 17 . Age 18 . Serum bilirubin &lt; = 1.5 time upper limit normal ( ULN ) . Serum aspartate aminotransferase alanine aminotransferase &lt; = 2.5 time ULN . Serum creatinine &lt; 200 umol/L Uncontrolled nausea vomit within 48 hour prior start induction therapy . Grade 01 nausea permit start induction . Known hypersensitivity granisetron aprepitant . Patients currently receive treatment strong CYP3A4 inhibitor substrates treatment either discontinue switched different medication prior start study drug . Not able swallow absorb oral medication . Documented active central nervous system ( CNS ) leukemia recent CNS hemorrhage . Concomitant use : 1 . Other investigational agent induction therapy 2 . Radiotherapy , one month prior , induction therapy 3 . Systemic corticosteroid 4 . Other chemotherapy agent Days 18 Pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>AML</keyword>
</DOC>